HIGHLIGHTS
SUMMARY
Linking excess adiposity to ICI response in MCC patients could give more insights into the complex immune-metabolic interactions, serving as both predictive and stratification factors in future clinical trials. The Immune Checkpoint Inhibitors (ICIs), anti-PD-L1 avelumab and anti-PD-1 pembrolizumab, have been recently approved as firstline treatment in metastatic MCC, although only a minority of patients exhibit long-term response. The clinical, contrasting, observation of improved outcomes in obese patients following treatment with immune checkpoint blockade, known as the "obesity paradox", has been studied across many types of tumors. Probably . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.